Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 15, 2024

Real-World Use Patterns, Effectiveness, and Tolerability of Sacituzumab Govitecan for the Second-Line and Later-Line Treatment of Metastatic TNBC in the US

Breast Cancer Research and Treatment

 

Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research and Treatment
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States
Breast Cancer Res Treat 2024 Jun 21;[EPub Ahead of Print], K Kalinsky, L Spring, C Yam, MA Bhave, I Ntalla, C Lai, N Sjekloca, B Stwalley, M Stokes, A Taylor, R Nanda

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading